查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995490

数位偏头痛治疗设备市场：按设备类型、技术、最终用户和分销管道划分－2026-2032年全球市场预测

Digital Migraine Treatment Devices Market by Device Type, Technology, End-User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，数位偏头痛治疗设备市场价值将达到 1.3743 亿美元，到 2026 年将成长到 1.6127 亿美元，到 2032 年将达到 4.1696 亿美元，年复合成长率为 17.18%。

主要市场统计数据
基准年 2025 1.3743亿美元
预计年份：2026年 1.6127亿美元
预测年份 2032 4.1696亿美元
复合年增长率 (%) 17.18%

全面介绍了偏头痛治疗的现状，神经调控、患者赋权和临床整合的创新正在重塑治疗路径。

由于技术创新、治疗路径的转变以及患者对非药物疗法的需求日益增长，偏头痛治疗正处于转折点。数位偏头痛治疗设备融合了神经调控、感测器整合和以使用者为中心的设计等方面的进步，提供差异化的治疗方案，并能无缝融入日常生活。随着患者对偏头痛的了解和资讯获取管道的增加，临床医生和医疗保健系统正在重新思考治疗流程，并在临床适宜的情况下，将这些设备与传统药物联合使用或作为传统药物的替代方案。

技术成熟度、数位生态系统和不断变化的报销环境如何从根本上改变偏头痛治疗的临床应用和竞争策略。

偏头痛治疗设备领域的变革性变化正在重塑市场竞争动态和临床实践。神经调控技术的进步，例如远端控制电刺激和标靶磁疗，已从小众临床研究发展成为门诊和居家照护的广泛应用。同时，设备设计也得到了改进，更加重视舒适性、易用性和患者无缝衔接，从而减少了临床实践中的摩擦，并提高了患者的长期治疗依从性。

我们将评估关税政策的变化如何促使供应链重组、重新评估定价策略，以及更重视整个设备组合的製造韧性。

关税的引入对供应链、定价策略和市场进入计划都产生了影响，进而影响相关人员的产品采购和地理扩张方式。 2025年，美国关税政策的变化促使医疗设备製造商和经销商重新评估其筹资策略，并专注于零件产地、契约製造和物流路线。拥有垂直整合供应链和多元化製造地的公司能够透过重新分配生产和与供应商重新谈判合约条款来减轻最严重的衝击。

将设备外形规格、神经调节方式、医疗保健环境和分销方式与个人商业化策略联繫起来的全面细分洞察。

深入的市场区隔分析揭示了产品设计、技术方法、医疗环境和分销策略如何影响市场接受通路和商业重点。根据设备类型，市场细分为手持设备、植入式设备和穿戴式装置。每种外形规格都对应着不同的临床价值提案。手持装置专注于便携性和间歇性使用，植入式装置强调透过持续神经调控进行慢性疾病管理，而穿戴式装置则提供持续监测和便利的预防策略。这些差异会影响产品开发蓝图、临床试验设计以及最终用户教育需求。

监管环境、支付方环境以及临床应用方面的区域差异，使得在全球主要市场中取得商业性成功需要製定针对特定区域的策略。

区域趋势持续以独特的方式影响临床准入路径、监管预期和合作机会。在美洲，重点在于透过已建立的临床网络、与支付方的合作以及商业化实现快速的临床应用。医疗器材开发商通常优先考虑严谨的临床试验设计和以支付方为导向的证据，以支持产品整合到门诊神经科和基层医疗医疗服务路径中。在欧洲、中东和非洲（EMEA）地区，由于法规环境和支付方结构的多样性，通常需要针对当地情况制定证据和针对特定国家的报销策略，才能成功推广。在这些市场，与专科医疗中心和区域分销商的合作项目通常能够加速产品的市场接受度。

领先的医疗设备创新者如何利用临床证据、生态系统伙伴关係和模组化产品设计，在偏头痛治疗领域建立可持续的竞争优势。

数位偏头痛治疗设备领域的主要企业正透过结合临床证据、易用性、经销伙伴和生态系统整合来脱颖而出。领先的创新者正投资于可操作的临床试验和患者报告结局指标 (PRO)，以证明其治疗价值并促进与支付方和医疗保健系统的谈判。同时，与专科诊所、远端医疗提供者和復健网络建立策略合作伙伴关係，使企业能够更有效地扩大临床医生教育和患者接受度。

为经营团队提供切实可行的策略建议，以协调证据产生、供应链韧性和以客户为中心的商业化，从而实现永续的市场优势。

产业领导者应优先考虑整合临床检验、供应链韧性和以客户为中心的商业化策略，以创造可持续的成长机会。首先，他们需要投资于多元化证据的收集，将随机对照试验、真实世界註册研究和患者报告结局相结合，从而同时满足临床医生、支付者和患者的需求。这种综合证据策略，若与可操作的诊疗路径相结合，将有助于推动医保报销方面的讨论，并加速技术的普及应用。

采用透明的混合方法调查方法，结合专家访谈、证据检验验证和案例研究，以确保为决策者提供可操作且检验的见解。

本研究采用混合方法，旨在确保分析的严谨性和实际应用性。关键的定性资料包括对神经科、疼痛专家、临床试验主要研究者、采购经理和医疗设备开发人员的结构化访谈，从而深入了解临床决策者、推广应用的障碍以及营运限制。此外，本研究还对同行评审文献、监管申报文件、临床试验註册资讯和公共声明进行了二次分析，以检验临床结论并阐明监管趋势。

结论强调，证据、互通性和营运弹性决定了哪些创新能够永续改善患者预后和商业性可行性。

总而言之，数位偏头痛治疗领域正从早期创新阶段迈向系统性的临床和商业性整合阶段。神经调控技术的进步，加上设备人体工学的改进以及与数位医疗的融合，正在拓展治疗选择，并催生超越传统诊所环境的医疗服务模式。那些优先考虑建立可靠证据、提升供应链柔软性以及以客户为中心的产品设计的相关人员，将更有能力把临床潜力转化为可持续的市场地位。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：数位偏头痛治疗设备市场：依设备类型划分

  • 携带式
  • 嵌入式装置
  • 穿戴式装置

第九章：数位偏头痛治疗设备市场：依技术划分

  • 远程电神经元调製（REN）
  • 经颅磁刺激（TMS）
  • 经皮电神经刺激（TENS）
  • 迷走神经刺激术（VNS）

第十章：数位偏头痛治疗设备市场：以最终用户划分

  • 居家医疗环境
  • 医院和诊所
  • 专业医疗中心

第十一章：数位偏头痛治疗设备市场：依通路划分

  • 离线
  • 在线的

第十二章：数位偏头痛治疗设备市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：数位偏头痛治疗设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：数位偏头痛治疗设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国数位偏头痛治疗设备市场

第十六章：中国数位偏头痛治疗设备市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • CEFALY Technology
  • Chordate Medical Holding AB
  • Cirrus Healthcare Products LLC
  • Dr Reddy's Laboratories Ltd.
  • electroCore, Inc.
  • eNeura Inc.
  • Hi-Dow International Inc.
  • LivaNova PLC
  • Neurolief Ltd.
  • Nocira, LLC
  • Salvia BioElectronics BV
  • ShiraTronics, Inc.
  • Soterix Medical Inc.
  • Theranica Bio-Electronics Ltd.
  • Tivic Health Systems, Inc.
  • tVNS technologies GmbH
  • WELT Corp.
Product Code: MRR-FB6C9E792BE4

The Digital Migraine Treatment Devices Market was valued at USD 137.43 million in 2025 and is projected to grow to USD 161.27 million in 2026, with a CAGR of 17.18%, reaching USD 416.96 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 137.43 million
Estimated Year [2026] USD 161.27 million
Forecast Year [2032] USD 416.96 million
CAGR (%) 17.18%

A comprehensive introduction to the convergence of neuromodulation innovation, patient empowerment, and clinical integration that is reshaping migraine treatment pathways

The landscape of migraine care is experiencing an inflection point driven by technological innovation, shifting care pathways, and growing patient demand for nonpharmacologic options. Digital migraine treatment devices are converging advances in neuromodulation, sensor integration, and user-centered design to offer differentiated therapeutic choices that integrate with everyday life. Patients are increasingly informed and connected, prompting clinicians and health systems to re-evaluate therapeutic algorithms and incorporate devices alongside or in place of traditional medications when clinically appropriate.

Clinicians report improved engagement and adherence when treatment modalities provide immediate feedback, remote monitoring, and personalized titration. Concurrently, developers are focusing on ergonomics, wearability, and evidence generation that aligns with clinical endpoints. Payers and providers are showing greater interest in outcomes-based approaches that link device use to real-world effectiveness, which in turn influences procurement and reimbursement conversations.

As a result, the sector is shifting from early adopter enthusiasm toward more structured clinical and commercial pathways. Regulatory clarity, patient-reported outcome validation, and interoperability with digital health ecosystems are now primary considerations for organizations evaluating device portfolios. The introduction of clinically validated, user-friendly neuromodulation options has created a fertile environment for cross-disciplinary collaboration and strategic investments in product differentiation, care integration, and long-term patient engagement.

How technological maturation, digital ecosystems, and evolving reimbursement dynamics are fundamentally transforming clinical adoption and competitive strategy in migraine treatment

Transformative shifts within the migraine device landscape are redefining competitive dynamics and clinical practice. Advances in neuromodulation modalities, such as remotely administered electrical stimulation and targeted magnetic approaches, have matured from niche clinical studies to broader implementation across ambulatory and homecare settings. This technological maturation is accompanied by design improvements that prioritize wearability, ease of use, and seamless patient onboarding, thereby reducing friction at the point of care and improving long-term adherence.

Parallel to device evolution, digital ecosystems that support remote monitoring, data capture, and telehealth integration are becoming essential components of commercially viable offerings. These ecosystems enable longitudinal outcome tracking, facilitate clinician oversight, and create opportunities for value-based contracting by linking utilization patterns to clinical outcomes. At the same time, reimbursement frameworks are evolving incrementally to reflect the clinical value of device-based therapies, prompting manufacturers to invest in robust evidence generation, health-economics analyses, and pragmatic studies.

Strategic collaborations among device developers, academic centers, and specialty clinics are accelerating translational research and real-world validation. As stakeholders align around clinically meaningful endpoints and patient-centric trial designs, the market is moving toward greater standardization in clinical practice, which improves comparability across modalities and strengthens payer confidence.

Assessing how tariff policy changes have prompted supply chain realignment, pricing strategy recalibration, and heightened emphasis on manufacturing resilience across device portfolios

The introduction of tariffs can ripple across supply chains, pricing strategies, and market access plans, shaping how stakeholders approach product sourcing and geographic expansion. In 2025, tariff policy developments in the United States prompted device manufacturers and distributors to reassess sourcing strategies, with attention to component provenance, contract manufacturing, and logistics routing. Companies with vertically integrated supply chains or diversified manufacturing footprints were able to mitigate the most acute impacts by reallocating production volumes and renegotiating supplier terms.

These trade adjustments also influenced commercial pricing strategies. Some organizations absorbed incremental costs to preserve competitive pricing in core markets, while others adjusted list prices selectively where reimbursement dynamics permitted. For exporters and multinational manufacturers, tariff incidence necessitated more sophisticated cost-to-serve models that explicitly accounted for customs duties, compliance costs, and longer lead times. This, in turn, affected inventory planning and working capital management as firms sought to balance service levels with cost containment.

Beyond immediate financial implications, tariff-driven shifts accelerated strategic moves to regionalize supply chains and deepen local manufacturing partnerships. The experience underlined the importance of scenario planning and supply-chain resilience, encouraging manufacturers to build flexible sourcing arrangements and maintain transparent supplier relationships to preserve market continuity during periods of trade uncertainty.

Comprehensive segmentation insights linking device form factors, neuromodulation modalities, care settings, and distribution approaches to tailored commercialization strategies

Insightful segmentation analysis reveals how product design, technological modality, care setting, and distribution approach shape adoption pathways and commercial priorities. Based on Device Type, the market is studied across Handheld Devices, Implantable Devices, and Wearable Devices, where each form factor creates distinct clinical value propositions: handheld devices prioritize portability and episodic use, implantable options emphasize chronic management with sustained neuromodulation, and wearables deliver continuous monitoring and convenience for preventive strategies. These differences influence product development roadmaps, clinical trial designs, and end-user education requirements.

Based on Technology, the market is studied across Remote Electrical Neuromodulation (REN), Transcranial Magnetic Stimulation (TMS), Transcutaneous Electrical Nerve Stimulation (TENS), and Vagus Nerve Stimulation (VNS), each representing a unique efficacy and safety profile that must be matched to patient phenotypes and treatment goals. Technology choice affects clinical training needs, regulatory pathways, and post-market surveillance approaches, and it informs the type of clinical evidence sponsors prioritize. Based on End-User, the market is studied across Homecare Settings, Hospitals & Clinics, and Specialty Centers, highlighting how care delivery context dictates device features, integration needs, and support models; homecare adoption emphasizes user-friendly interfaces and remote support, whereas hospitals and specialty centers demand interoperability with clinical systems and rigorous device lifecycle management. Based on Distribution Channel, the market is studied across Offline and Online, underscoring how omnichannel strategies are required to reach both clinician-led procurement and direct-to-consumer adoption, with implications for marketing, reimbursement navigation, and patient education.

Taken together, these segmentation lenses inform targeted commercialization strategies by clarifying which product attributes, evidence packages, and customer engagement models are required to achieve sustained uptake in each subsegment.

Regional differentiation in regulatory frameworks, payer landscapes, and clinical adoption that demands tailored strategies for commercial success across key global territories

Regional dynamics continue to shape clinical adoption pathways, regulatory expectations, and partnership opportunities in distinctive ways. The Americas market demonstrates a strong focus on rapid clinical translation, payer engagement, and commercialization through established clinical networks; device developers often prioritize robust clinical trial designs and payer-oriented evidence to support integration into outpatient neurology and primary care pathways. Europe, Middle East & Africa combines diverse regulatory environments with varied payer structures, creating a landscape where localized evidence generation and country-specific reimbursement strategies are frequently required for successful rollout. In these markets, collaborative programs with specialty centers and regional distributors often accelerate acceptance.

Asia-Pacific exhibits a heterogeneous mix of highly competitive domestic manufacturers and multinational entrants, with particular emphasis on scalable manufacturing, cost-effective designs, and mobile health integration to meet broad patient demand. Strategic partnerships with local clinical institutions and targeted regulatory navigation are common approaches to market entry. Across all regions, digital health interoperability and telemedicine adoption are converging with device deployment strategies, enabling more efficient remote monitoring and expanding access to care beyond traditional clinic walls.

Ultimately, regional strategies benefit from a nuanced appreciation of local regulatory frameworks, reimbursement contours, and clinical practice patterns, with successful entrants tailoring evidence generation, distribution models, and customer engagement to the priorities of each geography.

How leading device innovators are leveraging clinical evidence, ecosystem partnerships, and modular product design to create durable competitive differentiation in migraine care

Key companies in the digital migraine device realm are differentiating through a combination of clinical evidence, product usability, distribution partnerships, and ecosystem integrations. Leading innovators are investing in pragmatic clinical trials and patient-reported outcome measures to substantiate therapeutic value and to facilitate discussions with payers and health systems. At the same time, strategic alliances with specialty clinics, telehealth providers, and rehabilitation networks are helping companies to scale clinician education and patient onboarding more efficiently.

Product roadmaps emphasize modularity, firmware upgradability, and secure data platforms that support longitudinal outcome measurement and regulatory compliance. Several firms are also pursuing label expansions by collaborating with academic centers on investigator-initiated studies that explore new therapeutic indications or subpopulations. Distribution strategies are evolving to balance clinician-directed channels with direct-to-consumer offerings, supported by digital marketing and remote training to maintain clinical oversight.

Operationally, companies are strengthening their post-market surveillance and customer support infrastructures to capture real-world data and to respond rapidly to usability or safety signals. These capabilities not only support regulatory obligations but also generate insights that feed back into product improvement cycles and commercial differentiation.

Actionable strategic recommendations for executives to align evidence generation, supply-chain resilience, and customer-centric commercialization for sustainable market advantage

Industry leaders should prioritize an integrated approach that aligns clinical validation, supply-chain resilience, and customer-centric commercialization to unlock sustained growth opportunities. First, invest in diversified evidence generation that combines randomized studies with real-world registries and patient-reported outcomes to address the needs of clinicians, payers, and patients simultaneously. This mixed evidence strategy supports reimbursement discussions and accelerates adoption by aligning with pragmatic care pathways.

Second, build supply-chain flexibility through multi-sourcing, regional manufacturing partnerships, and transparent supplier relationships to reduce vulnerability to trade disruptions and to shorten lead times. Incorporate scenario planning into procurement and financial models to prepare for potential tariff, logistic, or component shortages. Third, design product and service bundles that reflect the use context-homecare solutions should prioritize usability and remote support, whereas hospital-facing offerings must emphasize interoperability and enterprise-grade service agreements. Finally, cultivate strategic collaborations with telehealth providers, specialty centers, and patient advocacy organizations to expand access, improve onboarding, and strengthen post-market evidence collection. These partnerships can also facilitate pilot programs that demonstrate cost-effectiveness in real-world clinical workflows.

By executing on these priorities, leaders can align innovation with market realities, reduce commercial friction, and create defensible pathways to adoption.

A transparent mixed-methods research methodology integrating expert interviews, evidence triangulation, and case analysis to ensure actionable and validated insights for decision-makers

This research employs a mixed-methods approach designed to ensure analytical rigor and pragmatic applicability. Primary qualitative inputs include structured interviews with neurologists, pain specialists, clinical trial investigators, procurement leads, and device developers, which provide insights into clinical decision drivers, adoption barriers, and operational constraints. These interviews are complemented by secondary analysis of peer-reviewed literature, regulatory filings, clinical trial registries, and public policy statements to validate clinical claims and to contextualize regulatory trends.

Evidence synthesis prioritizes triangulation across sources to reduce bias and to increase confidence in thematic findings. The methodology also incorporates case studies of device implementations across ambulatory, hospital, and specialty care contexts to illustrate practical deployment considerations. Throughout the analysis, attention is given to product usability, integration into care pathways, and post-market surveillance frameworks to ensure the findings are actionable for commercial leaders.

Data integrity is maintained through source verification, expert validation of key themes, and sensitivity checks for areas where evidence is still emerging. The methodological framework emphasizes transparency in assumptions and limitations, and results are presented with clear contextual qualifiers where definitive conclusions are constrained by available evidence.

Concluding synthesis emphasizing how evidence, interoperability, and operational resilience will determine which innovations sustainably improve patient outcomes and commercial viability

In summary, the digital migraine treatment landscape is transitioning from early innovation toward structured clinical and commercial integration. Advances in neuromodulation technologies, combined with improvements in device ergonomics and digital health integration, are expanding therapeutic choices and enabling care delivery models that extend beyond traditional clinic walls. Stakeholders who prioritize robust evidence generation, supply-chain flexibility, and customer-centric product design are positioned to convert clinical potential into durable market presence.

Regulatory clarity, strategic partnerships, and regionalized approaches remain critical to navigating diverse market dynamics and payer expectations. As the ecosystem matures, longitudinal outcome measurement and interoperability with broader digital health systems will become central to demonstrating value and achieving scale. For manufacturers and investors, the practical imperatives are clear: align product development with real-world care workflows, invest in multimodal evidence, and build resilient commercial operations that can adapt to regulatory and trade developments. By doing so, organizations can more effectively translate technological promise into improved patient outcomes and sustainable commercial models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Digital Migraine Treatment Devices Market, by Device Type

  • 8.1. Handheld Devices
  • 8.2. Implantable Devices
  • 8.3. Wearable Devices

9. Digital Migraine Treatment Devices Market, by Technology

  • 9.1. Remote Electrical Neuromodulation (REN)
  • 9.2. Transcranial Magnetic Stimulation (TMS)
  • 9.3. Transcutaneous Electrical Nerve Stimulation (TENS)
  • 9.4. Vagus Nerve Stimulation (VNS)

10. Digital Migraine Treatment Devices Market, by End-User

  • 10.1. Homecare Settings
  • 10.2. Hospitals & Clinics
  • 10.3. Specialty Centers

11. Digital Migraine Treatment Devices Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Digital Migraine Treatment Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Digital Migraine Treatment Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Digital Migraine Treatment Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Digital Migraine Treatment Devices Market

16. China Digital Migraine Treatment Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. CEFALY Technology
  • 17.6. Chordate Medical Holding AB
  • 17.7. Cirrus Healthcare Products LLC
  • 17.8. Dr Reddy's Laboratories Ltd.
  • 17.9. electroCore, Inc.
  • 17.10. eNeura Inc.
  • 17.11. Hi-Dow International Inc.
  • 17.12. LivaNova PLC
  • 17.13. Neurolief Ltd.
  • 17.14. Nocira, LLC
  • 17.15. Salvia BioElectronics B.V.
  • 17.16. ShiraTronics, Inc.
  • 17.17. Soterix Medical Inc.
  • 17.18. Theranica Bio-Electronics Ltd.
  • 17.19. Tivic Health Systems, Inc.
  • 17.20. tVNS technologies GmbH
  • 17.21. WELT Corp.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY HANDHELD DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY HANDHELD DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY HANDHELD DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY REMOTE ELECTRICAL NEUROMODULATION (REN), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY REMOTE ELECTRICAL NEUROMODULATION (REN), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY REMOTE ELECTRICAL NEUROMODULATION (REN), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION (TMS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION (TMS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION (TMS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY VAGUS NERVE STIMULATION (VNS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY VAGUS NERVE STIMULATION (VNS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY VAGUS NERVE STIMULATION (VNS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GCC DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. GCC DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. GCC DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 93. GCC DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. G7 DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. G7 DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. G7 DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 108. G7 DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. NATO DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NATO DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. NATO DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. NATO DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. UNITED STATES DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. CHINA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA DIGITAL MIGRAINE TREATMENT DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)